Prostin E2

Quick links to important sections

Prostin E2

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostin E2

What is Prostin E2?

Prostin E2 is a pharmaceutical preparation of dinoprostone, a naturally occurring substance known as prostaglandin E2 (PGE2). In the human body, prostaglandins are lipid compounds that have hormone-like effects and are involved in various physiological processes, including the regulation of inflammation, blood flow, and muscular contractions.

Mechanism of Action

Prostin E2 works by mimicking the actions of natural prostaglandins in the female reproductive system. It interacts with specific receptors in the tissues of the cervix and the uterus. When applied, it facilitates several biological changes:

  • Cervical Ripening: It promotes the breakdown of collagen within the cervix, causing it to soften, thin, and dilate. This process is a necessary precursor to childbirth.
  • Uterine Stimulation: It can stimulate the smooth muscles of the uterus, leading to rhythmic contractions.

Clinical Applications

This medication is primarily utilized in obstetric care for specific indications related to pregnancy and labor. Its use is generally categorized into two main areas:

Labor Induction

Prostin E2 is used to initiate or medicalize the process of labor when the cervix is not yet prepared for delivery. By "ripening" the cervix, it increases the likelihood of a successful vaginal birth.

Pregnancy Termination

In certain clinical scenarios, Prostin E2 is employed to evacuate the uterine contents. This includes the management of missed abortions (where the pregnancy has ended but the tissue remains in the uterus) or for the termination of pregnancy during the second trimester.

Regulatory References

  1. NIH StatPearls Monograph on Prostaglandin E2 (Dinoprostone)

What side effects are possible with Prostin E2?

Possible Side Effects and Safety Information

The safety profile of Dinoprostone (Prostin E2) is strictly documented in official regulatory sources, with potential side effects classified by the frequency of their occurrence and the physiological system affected. The regulatory documentation emphasizes that administration must only occur in a clinical setting equipped for continuous fetal and uterine monitoring.


Frequency Classification of Adverse Reactions

The following is a summary of adverse reactions classified by frequency in regulatory documentation:

  • Very Common Reactions: These frequently observed effects primarily involve the Gastrointestinal System, typically manifesting as nausea, vomiting, and diarrhoea.
  • Common Reactions: These include effects on the Reproductive System such as uterine hypertonus (excessive muscle tone) and uterine contraction disorders. Foetal distress or changes in foetal heart rate are also classified as common effects. Other common effects include headache and fever (pyrexia).
  • Rare Reactions: This category includes serious but infrequently occurring events.

Serious Adverse Reactions and Safety Considerations

Official labeling identifies specific serious risks, reflecting the potent oxytocic action of the medicine. Uterine rupture is a documented, rare, and serious risk. The severe blood disorder Disseminated Intravascular Coagulation (DIC) is also identified as a rare event, particularly noted in the post-partum period following labor induction. The risk of DIC is officially noted to be increased in women with advanced maternal age (over 35 years) and high parity (four or more previous term deliveries).

Administration-Agnostic Safety Constraints define absolute restrictions. The medicine is contraindicated in patients with conditions such as a history of Pelvic Inflammatory Disease (PID), unexplained vaginal bleeding, and pre-existing foetal distress.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Dinoprostone (Prostin E2) is primarily characterized by the exaggeration of its documented oxytocic effects, according to official government regulatory sources.

Documented Overdose Manifestations

Classification Official Regulatory Statement
Primary Manifestation Uterine hyperstimulation (hypertonus or hypercontractility) due to excessive uterotonic activity.
Associated Outcome Fetal distress, indicated by abnormalities in the fetal heart rate, which requires prompt attention.
Severe Outcomes Life-threatening complications, including uterine rupture and potential fetal death, particularly in uncontrolled cases.

Required Emergency Actions

The appearance of signs of uterine hyperstimulation or fetal distress constitutes a medical emergency that requires immediate medical attention. Regulators mandate the prompt removal (discontinuation) of the dinoprostone dosage form to halt further drug exposure. As no specific antidote is known, the management is officially described as symptomatic and supportive. This may include the use of tocolytic agents to reduce excessive uterine activity and continuous monitoring of both maternal and fetal status. The overdose profile is designed to guide immediate, high-risk intervention based on documented clinical and physiological findings.

Therapeutic Uses of Prostin E2

What Prostin E2 Treats: Main Uses and Benefits

Prostin E2, which contains dinoprostone, is commonly used across therapeutic domains where additional symptomatic support is needed, primarily in the context of pregnancy. This medication is applied in addressing conditions where functional stability becomes affected, often near the end of pregnancy.

This key application of dinoprostone is relevant in conditions characterized by periods of heightened symptoms associated with acute or episodic changes. Its application is relevant when supportive symptom management is appropriate in the context of a planned medical procedure. This assists with maintaining functional stability and is applied in addressing symptoms linked to organ-specific functional stress. Prostin E2 is considered relevant for easing symptom clusters that may become intense or disruptive in clinical scenarios where short-term stabilization is important. It supports patients during episodes of heightened discomfort by contributing to easing the overall symptom load.

“Prostin E2's role is to help provide support that eases the overall symptom burden during necessary clinical phases.”

Quick Fact: Supports symptoms related to physical discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Prostin E₂ (Dinoprostone) is an oxytocic agent whose use is tightly defined by regulatory eligibility rules. The medicine is primarily intended for adults and adolescents for specific obstetric applications, namely cervical ripening or labor induction in pregnant women at or near term, or for uterine content evacuation. Use is contraindicated for labor induction before 37 completed weeks of gestation. The medicine is not established for use in general pediatric patients and is not indicated during the lactation period.


Absolute Contraindications

The medicine must not be used in patients with a known hypersensitivity to prostaglandins, a history of Caesarean section or major uterine surgery, Grand Multiparae (six or more term pregnancies), cephalopelvic disproportion (CPD), or those with signs of fetal compromise. It is also contraindicated in cases of placenta previa, unexplained vaginal bleeding, or pre-existing uterine hypertonus.


Restrictions and Cautions

Specific conditions require cautionary use. This includes patients with impaired renal, hepatic, or cardiovascular function, as well as pre-existing conditions like asthma or glaucoma. Conditional use is required for women aged 35 years or older or those with postdate pregnancy, due to an officially documented increased risk of post-partum Disseminated Intravascular Coagulation (DIC).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Prostin E2 (dinoprostone) documents interactions primarily within the class of Oxytocic Agents, which are medicines used to stimulate uterine activity. The core of this interaction is classified as an additive pharmacodynamic effect, where co-administration may augment or potentiate the activity of the other uterotonic substance.

Contraindicated and Restricted Combinations

The co-administration of dinoprostone is subject to specific constraints and prohibitions detailed in official product labeling. Intravenous oxytocic agents are formally contraindicated for concurrent use with the dinoprostone vaginal insert formulation. Regulatory sources generally advise against the simultaneous use of any other oxytocic agent with dinoprostone.

Mandatory Timing Separation

Due to the risk of pharmacodynamic potentiation, mandatory timing separation is required for the sequential use of other oxytocic agents, such as Oxytocin. The precise required interval varies by the dinoprostone formulation:

  • Vaginal Insert: The device must be removed at least 30 minutes before the administration of any subsequent oxytocic agent.
  • Cervical Gel or Vaginal Tablets: A dosing interval of six to twelve hours is specified before commencing a sequential oxytocic agent.

No explicit interaction patterns involving CYP enzymes, drug transporters, food, alcohol, herbal products, or dietary supplements are documented in official regulatory interaction sections.

Mechanism of Action

How Prostin E2 Works: The Mechanism of Action

The action of Dinoprostone involves its function as a full agonist on all four subtypes of Prostaglandin E₂ (EP) receptors, triggering two simultaneous and distinct physiological cascades in the reproductive system.


Targeted Agonism to Initiate Uterine Contraction

Dinoprostone's binding to EP₁ and EP₃ receptors activates the Gq signaling pathway, leading to a rapid and localized increase in intracellular calcium ( Ca^2+) concentration within the myometrial smooth muscle cells. The resulting calcium surge directly causes the muscle fibers to shorten and contract, producing rhythmic and strong uterine contractions through myometrial smooth muscle cell shortening.


Enzymatic Remodeling for Cervical Softening

The parallel action involves the EP receptors found on the cervical tissue, which triggers a separate cascade leading to the increased local production of enzymes, such as collagenase. This enzymatic activity breaks down the dense, rigid collagen fiber network that provides structural integrity to the cervix. This structural modification causes the cervix to soften, thin (efface), and dilate (open), which decreases the mechanical rigidity of the tissue.

Dosage and Administration Information

Administration Scope: Official Administration Guidelines

The usage of dinoprostone is strictly confined to hospital settings and must be performed solely by trained obstetrical healthcare personnel. The product's administration is local, utilizing the vaginal or endocervical route, and the dosage schedule is entirely dependent on the specific formulation being used.

Property Official Instruction Summary
Route of administration Intravaginal (insert, suppository, or tablet) or Endocervical (gel).
Dosing schedule Vaginal Insert (10 mg): Administered as a single, time-limited dose. Endocervical Gel (0.5 mg): An initial 0.5 mg dose, which may be repeated once after a 6-hour interval (maximum of 1.5 mg within 24 hours). Vaginal Suppository (20 mg): Subsequent 20 mg doses are administered at 3- to 5-hour intervals.
Preparation The vaginal insert is generally kept frozen until immediate use, while suppositories may be warmed to room temperature before insertion.
Age-group rules Use in pregnant girls (pediatric population) has not been established; no explicit dose adjustments are listed for older adults or patients with hepatic or renal impairment.

Resulting Procedural Structure

The overall use protocol for dinoprostone is defined by its intermittent, acute pattern, requiring strict adherence to timing rules. Following administration, the patient must remain in a recumbent position for a specified period, ranging from 10 minutes to two hours depending on the form, to ensure proper application. The course of treatment is short-term; for instance, the vaginal insert must be removed after 12 hours or earlier upon the onset of active labor. Furthermore, the product must be removed or discontinued for a mandatory interval (ranging from 30 minutes to 12 hours) before the sequential administration of oxytocic agents is initiated.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prostin E₂ (Dinoprostone)

Evidence for use in Cervical Ripening and Labor Induction

The research base includes numerous Randomized Controlled Trials (RCTs). The findings from these trials have been combined in Systematic Reviews to examine the consistency of observed outcomes.

Studies were conducted during periods of increased symptom activity in pregnant women near term, focusing on those whose cervix was not yet considered fully ready for delivery. Research examined specific groups, such as first-time mothers, in these trials. Researchers monitored short-term, acute outcomes, including the achievement of cervical ripening, and outcomes related to the monitored delivery process.

Studies report measurements of the interval from administration to vaginal delivery in the observed populations. Trial reports describe patterns related to the rates of Cesarean Section observed in the studies and the frequency of requiring subsequent oxytocin augmentation once labor began. The research provides context into short-term changes.

The documentation of these studies describes what has been observed so far. Findings describe group patterns, not personal outcomes.

Evidence for use in Uterine Content Evacuation

Research has explored the use of Dinoprostone in specific clinical scenarios requiring the evacuation of uterine contents, such as in the management of non-viable pregnancies. This research is based on Clinical Trials conducted during periods of increased symptom activity and focuses on conditions associated with acute or disruptive episodes.

In these studies, researchers monitored outcomes related to the monitored delivery process, with the main outcome focused on the time interval for complete evacuation of the uterine contents. The study results reflect the specific clinical conditions under which they were conducted.

Key Uncertainties and Research Gaps

One key gap is that the follow-up durations were short, confining most knowledge to the immediate outcome of delivery. Long-term effects are not fully established for the mother or child. Furthermore, comparative evidence is lacking against all non-drug induction methods. Findings were mixed across studies when certain comparisons were examined. Data for certain groups, such as those with high Body Mass Index (BMI), remain insufficient.

Key Studies & References

  1. Prostin E2 Vaginal Tablets (Dinoprostone) - Summary of Product Characteristics (SPC)
  2. NG207: Inducing labour - NICE Guideline Recommendations

Frequently Asked Questions (FAQ)

Common questions about Prostin E2 (FAQ)


Q: Is Prostin E2 the same as misoprostol?

A: Prostin E2, which contains the active substance dinoprostone, is not the same medicine as misoprostol. However, both belong to the prostaglandin class of medicines that act on the uterus. Official warnings indicate that using them concurrently is generally avoided due to the documented risk of overstimulation or uterine injury.


Q: Does Prostin E2 cause bleeding, and if so, how much is normal?

A: According to official product information, unexplained vaginal bleeding during pregnancy is listed as a reason not to use the medicine (a contraindication). While official documents do not typically describe expected mild bleeding, rare but serious events like uterine hemorrhage (severe bleeding) are risks associated with uterine hyperstimulation. Due to these documented risks, continuous patient monitoring is a required protocol when this medicine is administered.


Q: Can Prostin E2 interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

A: The regulatory documents primarily focus on interactions with other oxytocic agents (medicines that stimulate the uterus) and do not explicitly list interactions with common pain relievers like ibuprofen or acetaminophen. Dinoprostone is a prostaglandin, and some pain relievers (NSAIDs like ibuprofen) work by inhibiting prostaglandins. Since this medicine is only used in a hospital setting, the healthcare team is responsible for reviewing and managing all concurrent medications during the hospital stay.


Q: How does the body eliminate Prostin E2 after it has been used?

A: The active substance, dinoprostone, is delivered locally to the cervix or vagina and is designed to work where it is placed. Once absorbed, it is rapidly metabolized (broken down) in organs like the lungs and liver and quickly converted into inactive substances. Because it has a very short half-life (the time it takes for the amount to reduce by half), the active drug itself is quickly eliminated from the body.


Q: Do regulatory agencies have a Black Box Warning on Prostin E2, and what does it mean?

A: Official product labeling contains extensive Warnings and Precautions regarding serious risks like uterine hyperstimulation and uterine rupture. While the US FDA label does not currently display a 'Black Box Warning' (the most severe type of warning), it does contain strict warnings. These warnings describe conditions that restrict the medicine’s use to hospital settings for continuous monitoring.


Q: Can I use Prostin E2 if I am taking blood thinners?

A: Official product information does not list an explicit interaction with standard blood thinners (anticoagulants). However, the active substance is part of a chemical family involved in regulating blood function. The official product information requires that all current medications, including blood thinners, are fully reviewed by the hospital healthcare team before administration due to the rare risk of a severe blood disorder known as Disseminated Intravascular Coagulation (DIC).


Q: What does 'contraindication' mean in relation to Prostin E2?

A: A contraindication is a medical condition or circumstance that makes the use of a particular drug inadvisable because it could cause harm. For Prostin E2, examples of contraindications include having a prior Caesarean section or a known hypersensitivity to prostaglandins. The medicine must not be used when these conditions are present.


Q: Does Prostin E2 contain any ingredients that may cause concern for certain populations?

A: Prostin E2 contains the active ingredient dinoprostone along with other components called excipients which vary by the product form. For example, some formulations may contain a small amount of alcohol (ethanol) or substances like lactose. If you have specific concerns about non-active ingredients, a full review of these ingredients with the healthcare team is a prudent step.


Q: What does 'half-life' mean for Prostin E2?

A: The half-life refers to the time needed for the amount of medicine in the body to drop to half of its initial level. Dinoprostone is noted to have a very short half-life—only about 1 to 3 minutes—because it is broken down so quickly after the body absorbs it.


Q: Does having allergies to other drugs affect eligibility for Prostin E2?

A: The medicine is contraindicated if a patient has a known hypersensitivity (severe allergic reaction) specifically to prostaglandins or any of the product’s non-active ingredients. While the label does not state that allergies to other unrelated drugs exclude a patient, this history, like all medication allergies, is included in the comprehensive review process conducted by the healthcare team before use.


Q: Can Prostin E2 cause changes in blood pressure or heart rate?

A: Yes, official documents report that common effects of the medicine include changes to the fetal heart rate. Less common effects reported in the mother include changes like hypertension (high blood pressure) and fluctuations in heart rate, such as a fast or slow heartbeat. Caution is advised for patients with pre-existing cardiovascular conditions.


Q: How is the need for Prostin E2 determined by a healthcare provider?

A: The need for this medicine is determined by a healthcare provider, such as a doctor or midwife, by thoroughly evaluating a patient's specific obstetric status and medical history. This process includes carefully checking that none of the official contraindications (reasons not to use the drug, like a previous C-section) are present before proceeding with administration.


Q: How long does the drug stay in the system after the last administration?

A: Because dinoprostone is eliminated so quickly from the body due to its very short half-life and rapid metabolism, the active substance itself does not persist in the body for a long duration after administration is complete or the device is removed.

How should Prostin E2 be stored and disposed of?

Storage and Disposal of Prostin E2

Storage requirements for Prostin E2 (dinoprostone) are strictly controlled and vary by formulation. The Vaginal Tablets and Sterile Solution must be stored under refrigeration at 2 C to 8 C. In contrast, the Vaginal Insert requires freezing until the time of immediate use and should not be warmed beforehand.

Stability and Handling

Some formulations have time limits; for example, the Sterile Solution must be used within 24 hours after dilution. All personnel must wash hands thoroughly after administration and prevent skin contact with the product. The medicine must be kept out of reach of children.

Disposal

Any unused medicinal product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste and should not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostin E2 found in:

A-Z Index: